PharmaEssentia (6446) Q2 2024 earnings summary

Executive summary

• Achieved strong revenue growth and returned to profitability for the six months ended June 30, 2024, compared to a net loss in the prior year period.

• Significant capital market activities included a major GDS issuance and new stock-based compensation plans.

• Ongoing international arbitration and legal proceedings with AOP Orphan Pharmaceuticals GmbH, with hearings completed and awaiting outcomes.

Financial highlights

• Operating revenue for H1 2024 was NTD 3,959,921 thousand, up 84% year-over-year from NTD 2,152,482 thousand.

• Net income for H1 2024 was NTD 1,010,206 thousand, compared to a net loss of NTD 938,296 thousand in H1 2023.

• Basic EPS for H1 2024 was NTD 3.05, versus a loss per share of NTD 2.98 in H1 2023.

• Gross margin improved to 88% in H1 2024 from 89% in H1 2023.

• Cash and cash equivalents stood at NTD 20,060,368 thousand as of June 30, 2024.

Outlook and guidance

• Management expects continued growth driven by global expansion and new product launches.

• Ongoing investments in R&D and manufacturing capacity to support future pipeline and market demand.